Gilenia Chemical Properties

Melting point:

103-105°

Boiling point:

479.5±45.0 °C(Predicted)

Density 

1.016

storage temp. 

Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

solubility 

Chloroform (Very Slightly, Heated), DMSO (Slightly, Heated), Methanol (Slightly,

pka

12.20±0.20(Predicted)

form 

Solid

color 

Off-White

InChI

InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3

InChIKey

KKGQTZUTZRNORY-UHFFFAOYSA-N

SMILES

C(O)C(N)(CCC1=CC=C(CCCCCCCC)C=C1)CO

Safety Information

WGK Germany 

WGK 3

Storage Class

11 - Combustible Solids

Hazard Classifications

Acute Tox. 4 Oral
Aquatic Acute 1
Aquatic Chronic 1
Repr. 2
Skin Irrit. 2
STOT RE 2

Gilenia Usage And Synthesis

Chemical Properties

white solid

Uses

Prophylaxis of organ rejection in patients receiving allogenic renal transplants (sphingosine-1-phosphate receptor).

Uses

Fingolimod is a novel immune modulator that prolongs allograft transplant survival in numerous models by inhibiting lymphocyte emigration from lymphoid organs.

Definition

ChEBI: An aminodiol that consists of propane-1,3-diol having amino and 2-(4-octylphenyl)ethyl substituents at the 2-position. It is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis. A prodrug, fingolimo is phosphorylated by sphingosine kinase to active metabolite fingolimod-phosphate, a structural analogue of sphingosine 1-phosphate.

Clinical Use

Sphingosine 1-phosphate receptor modulator:
Treatment of highly active relapsing-remitting multiple sclerosis

Drug interactions

Potentially hazardous interactions with other drugs
Anti-arrhythmics: possible increased risk of bradycardia with amiodarone, disopyramide and dronedarone.
Antifungals: concentration increased by ketoconazole.
Beta-blockers: possibly increased risk of bradycardia.
Calcium channel blockers: possible increased risk of bradycardia with diltiazem and verapamil.

Metabolism

Transformed by reversible stereoselective phosphorylation to the pharmacologically active (S)-enantiomer of fingolimod phosphate. It is eliminated by oxidative biotransformation mainly via the cytochrome P450 4F2 isoenzyme and subsequent fatty acid-like degradation to inactive metabolites, and by formation of pharmacologically inactive non-polar ceramide analogues of fingolimod. The main enzyme involved in the metabolism of fingolimod is partially identified and may be either CYP4F2 or CYP3A4. 81% excreted as inactive metabolites in the urine and <2.5% in the faeces as metabolites and unchanged drug.

Gilenia(162359-55-9)Related Product Information

• Fingolimod EP Impurity D
• Fingolimod Palmitate Amide
• Fingolimod Impurity 4
• Benzene, 1-(2-iodoethyl)-4-octyl-
• Fingolimod-d4
• 2-DiMethylaMino FingoliMod
• FTY720-d4 Hydrochloride
• diethyl 2-acetamido-2-(4-octylphenethyl)malonate
• 2-(4-OCTYLPHENYL)ETHANOL
• Fingolimod
• Fingolimod 2-Phenethyl Analog
• 2-NitrodeaMino FingoliMod
• 2-(Acetylamino)-2-[2-(4-octylphenyl)-2-oxoethyl]-propanedioic acid 1,3-diethyl ester
• N-(1-hydroxy-2-(hydroxymethyl)-4-(4-octylphenyl)butan-2-yl)acetamide
• DIMETHYL 2-(HYDROXYIMINO)MALONATE
• Fingolimod 3-Phenethyl Analog
• Fingolimod Impurity 42
• Fingolimod hydrochloride